| Literature DB >> 25870376 |
Wui-Jin Koh1, Benjamin E Greer1, Nadeem R Abu-Rustum1, Sachin M Apte1, Susana M Campos1, Kathleen R Cho1, Christina Chu1, David Cohn1, Marta Ann Crispens1, Oliver Dorigo1, Patricia J Eifel1, Christine M Fisher1, Peter Frederick1, David K Gaffney1, Ernest Han1, Warner K Huh1, John R Lurain1, David Mutch1, Amanda Nickles Fader1, Steven W Remmenga1, R Kevin Reynolds1, Nelson Teng1, Todd Tillmanns1, Fidel A Valea1, Catheryn M Yashar1, Nicole R McMillian1, Jillian L Scavone1.
Abstract
The NCCN Guidelines for Cervical Cancer provide interdisciplinary recommendations for treating cervical cancer. These NCCN Guidelines Insights summarize the NCCN Cervical Cancer Panel's discussion and major guideline updates from 2014 and 2015. The recommended systemic therapy options for recurrent and metastatic cervical cancer were amended upon panel review of new survival data and the FDA's approval of bevacizumab for treating late-stage cervical cancer. This article outlines relevant data and provides insight into panel decisions regarding various combination regimens. Additionally, a new section was added to provide additional guidance on key principles of evaluation and surgical staging in cervical cancer. This article highlights 2 areas of active investigation and debate from this new section: sentinel lymph node mapping and fertility-sparing treatment approaches.Entities:
Mesh：
Year: 2015 PMID： 25870376 DOI： 10.6004/jnccn.2015.0055
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908